

**Asymmetric Synthesis of Spiro[chroman-3,3'-pyrazol] Scaffolds with an All-carbon
Quaternary Stereocenter *via* a *oxa*-Michael-Michael Cascade Strategy with
Bifunctional Amine-thiourea Organocatalysts**

Weiping Zheng, Jiarong Zhang, Shuang Liu, and Zhiwei Miao*,^a

State Key Laboratory and Institute of Elemento-Organic Chemistry, Collaborative Innovation Center of
Chemical Science and Engineering (Tianjin), Nankai University, Weijin Road 94, Tianjin 300071 (P. R.

China) Fax: (+86)-22-2350-2351; e-mail: miaozhiwei@nankai.edu.cn

Supporting Information

List of contents (pages)

1. General comments.....	S1
2. Typical reaction procedure for the synthesis of spiro[chroman-3,3'-pyrazol] derivatives 11	S1
3. Characterizations of products 11a-t	S2
4. ¹ H-NMR and ¹³ C-NMR Spectra.....	S12
5. HPLC Spectra.....	S32
6. X-ray crystal structure of 11a	S52

General Comments:

Solvents were dried and distilled prior to use according to the standard methods. Unless otherwise indicated, all materials were obtained from commercial sources, and used as purchased without dehydration. Nitrogen gas (99.999%) was purchased from Boc Gas Inc. Flash column chromatography was performed on silica gel (particle size 10-40 μm , Ocean Chemical Factory of Qingdao, China). ¹H NMR, ¹³C NMR spectra were recorded in DMSO at Bruker AV 400 MHz spectrometers, TMS served as internal standard ($\delta = 0$ ppm). Data are presented as follows: chemical shift, integration, multiplicity (br = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, cm = complex multiplet) and coupling constant in Hertz (Hz). The crystal structure was determined on a Bruker SMART 1000 CCD diffractometer. The SHELXTL was used for structure solution and refinement. Mass spectra were recorded on a LCQ advantage spectrometer with ESI resource. HR-MS were recorded on APEXII and ZAB-HS spectrometer. Melting points were determined on a T-4 melting point apparatus (uncorrected). Optical rotations were recorded on a Perkin Elemer 241 Polarimeter.

Typical reaction procedure for the synthesis of spiro[chroman-3,3'-pyrazol] derivatives **11**:


(*E*)-2-(2-nitrovinyl)phenol **9** (0.5 mmol), catalyst **3** (15 mol%), additive BSA (15 mol%) and 4 Å MS (50 mg) in an oven-dried Schlenk tube were dissolved in 1 mL of anhydrous CH₃CN under nitrogen at 0 °C. Then 4-benzylidene-5-methyl-2-phenyl-pyrazolone **10** (0.6 mmol) was diluted with 1 mL of anhydrous CH₃CN and was added to the mixture by using a syringe. The mixture was stirred for the

corresponding time at 0 °C. The solvent was then removed under reduced pressure and the crude residue was purified by silica gel chromatography [petroleum ether/ethyl acetate 20:1 (v/v)] to give the corresponding products **11**.

Characterizations of products **11a-t**:

(2R,3R,4R)-3'-Methyl-4-(nitromethyl)-1',2-diphenyl spiro[chroman-3,4'-pyrazol]-5'(1'H)-one


(**11a**):



Light yellow solid; m.p. 154-155 °C. $[\alpha]_D^{25} = +68$ ($c = 1.0$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3): δ 7.49 (d, $J = 8.0$ Hz, 1H), 7.41 (t, $J = 7.0$ Hz, 2H), 7.24-7.38 (m, 7H), 7.18 (t, $J = 7.1$ Hz, 2H), 7.12 (t, $J = 7.5$ Hz, 2H), 5.44 (s, 1H), 4.83 (dd, $J = 7.7, 3.4$ Hz, 1H), 4.68 (dd, $J = 14.3, 7.7$ Hz, 1H), 4.19 (dd, $J =$

14.2, 3.4 Hz, 1H), 2.10 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3): δ 170.82, 157.34, 153.76, 136.65, 133.87, 130.00, 129.57, 129.40, 129.37, 128.80, 128.40, 127.06, 126.49, 126.44, 126.00, 122.89, 120.15, 119.59, 117.75, 117.62, 81.29, 75.97, 60.00, 38.64, 17.83. HRMS (ESI): calcd for $\text{C}_{25}\text{H}_{21}\text{N}_3\text{O}_4$ $[\text{M}+\text{H}]^+$: 428.1610, found: 428.1604. HPLC (Daicel Chiralpak ID-H: *n*-Hexane/*i*-PrOH /EtOH, 85:10:5 v/v, flow rate = 1.0 mL/min, column pressure = 42 bar, 23°C, UV 254 nm): t_r (minor) = 10.49 min, t_r (major) = 11.76 min.

(2R,3R,4R)-2-(2-Fluorophenyl)-3'-methyl-4-(nitromethyl)-1'-phenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (**11b**):




Yellow solid; m.p. 162-163°C. $[\alpha]_D^{25} = +60$ ($c = 1.0$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3): δ 7.51 (dd, $J = 8.6, 1.0$ Hz, 1H), 7.38-7.42 (m, 1H), 7.33-7.37 (m, 2H), 7.26-7.33 (m, 3H), 7.16-7.21 (m, 2H), 7.13 (dd, $J = 7.5, 3.9$ Hz, 2H), 7.04-7.07 (m, 2H), 5.79 (s, 1H), 4.87 (dd, $J = 7.9, 3.4$ Hz, 1H), 4.69 (dd, $J = 14.2, 7.9$

Hz, 1H), 4.17-4.22 (dd, $J = 14.2, 3.4$ Hz, 1H), 2.16 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3): δ 170.03, 157.15, 153.95, 136.73, 131.39, 130.89, 129.97, 129.57, 128.83, 128.40, 126.60, 125.89, 124.12, 123.04, 119.87, 119.37, 117.76, 117.56, 116.13, 115.91, 76.01, 75.91, 59.26, 38.94, 18.04. HRMS(ESI): calcd for $\text{C}_{25}\text{H}_{20}\text{FN}_3\text{O}_4$ $[\text{M}+\text{H}]^+$: 446.1516, found: 446.1514. HPLC (Daicel Chiralpak AD-H: *n*-

Hexane/*i*-PrOH, 95:5 v/v, flow rate = 1.0 mL/min, column pressure = 37 bar, 23°C, UV 254 nm): tr (minor) = 16.40 min, tr (major) = 25.43 min.


(2R,3R,4R)-2-(4-Fluorophenyl)-3'-methyl-4-(nitromethyl)-1'-phenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11c):



Yellow solid; m.p. 157-158 °C. $[\alpha]_D^{25} = +30$ ($c = 1.0$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3): δ 7.51 (d, $J = 7.7$ Hz, 1H), 7.38-7.42 (m, 1H), 7.33-7.37 (m, 2H), 7.26-7.34 (m, 3H), 7.16-7.21 (m, 2H), 7.13 (dd, $J = 7.5, 3.8$ Hz, 2H), 7.05 (t, $J = 9.0$ Hz, 2H), 5.79 (s, 1H), 4.87 (dd, $J = 7.8, 3.3$ Hz, 1H), 4.69 (dd, $J = 14.2, 7.9$ Hz, 1H), 4.20 (dd, $J = 14.2, 3.5$ Hz, 1H), 2.16 (s, 3H). ^{13}C NMR


(101 MHz, CDCl_3): δ 170.03, 157.16, 153.93, 136.71, 131.40, 129.97, 129.58, 128.83, 128.39, 126.61, 125.89, 124.13, 123.04, 119.87, 119.51, 119.37, 117.76, 117.56, 116.13, 115.90, 75.98, 75.91, 59.26, 38.93, 18.06. HRMS (ESI): calcd for $\text{C}_{25}\text{H}_{20}\text{FN}_3\text{O}_4$ $[\text{M}+\text{H}]^+$: 446.1516, found: 446.1514. HPLC (Daicel Chiralpak ID-H: *n*-Hexane/*i*-PrOH/EtOH, 85:10:5 v/v, flow rate = 1.0 mL/min, column pressure = 44 bar, 23°C, UV 254 nm): tr (minor) = 12.13 min, tr (major) = 10.58 min.

(2R,3R,4R)-2-(2-Chlorophenyl)-3'-methyl-4-(nitromethyl)-1'-phenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11d):



Light yellow solid; m.p. 173-174°C. $[\alpha]_D^{25} = +30$ ($c = 1.0$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3): δ 7.49-7.74 (m, 3H), 7.28-7.43 (m, 5H), 7.13-7.26 (m, 3H), 7.10 (t, $J = 7.8$ Hz, 2H), 5.32 (s, 1H), 4.81 (dd, $J = 7.8, 3.4$ Hz, 1H), 4.68 (dd, $J = 14.3, 7.7$ Hz, 1H), 4.19 (dd, $J = 14.2, 3.4$ Hz, 1H), 2.07 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3): δ 170.66, 157.13, 153.39, 136.54, 136.22, 132.46, 130.90, 130.12, 129.94, 129.68, 129.33, 128.91, 128.79, 126.50, 126.17, 125.16, 123.13, 122.47, 119.59, 117.63, 80.23, 75.85, 60.42, 38.52, 17.73. HRMS (ESI): calcd for $\text{C}_{25}\text{H}_{20}\text{ClN}_3\text{O}_4$ $[\text{M}+\text{H}]^+$: 462.1221, found: 462.1212. HPLC (Daicel Chiralpak ID-H: *n*-Hexane/*i*-PrOH/EtOH, 85:10:5 v/v, flow rate = 1.0 mL/min, column pressure = 44 bar, 23°C, UV 254nm): tr (minor) = 8.89 min, tr (major) = 9.82 min.

(2R,3R,4R)-2-(3-Chlorophenyl)-3'-methyl-4-(nitromethyl)-1'-phenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11e):




Light yellow solid; m.p. 172-173 °C. $[\alpha]_D^{25} = +68$ ($c = 1.0$, CH_2Cl_2). ^1H

NMR (400 MHz, CDCl_3): δ 7.49 (d, $J = 8.0$ Hz, 1H), 7.41 (t, $J = 7.0$ Hz, 2H), 7.28-7.36 (m, 6H), 7.18 (t, $J = 7.1$ Hz, 2H), 7.12 (t, $J = 7.5$ Hz, 2H),

5.42 (s, 1H), 4.81 (dd, $J = 7.9, 3.3$ Hz, 1H), 4.67 (dd, $J = 14.2, 7.9$ Hz, 1H),

4.18 (dd, $J = 14.2, 3.3$ Hz, 1H), 2.07 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3): δ 170.66, 157.13, 153.41, 136.57, 136.00, 134.43, 130.11, 129.68, 129.53, 129.35, 128.89, 126.50, 126.43, 126.14, 124.74, 123.12, 120.06, 119.55, 117.74, 117.62, 80.34, 75.85, 59.84, 38.56, 17.74. HRMS (ESI): calcd for $\text{C}_{25}\text{H}_{20}\text{ClN}_3\text{O}_4$ $[\text{M}+\text{H}]^+$: 462.1221, found: 462.1212. HPLC (Daicel Chiralpak ID-H: *n*-Hexane/*i*-PrOH/EtOH, 85:10:5 v/v, flow rate = 1.0 mL/min, column pressure = 44 bar, 23°C, UV 254 nm): tr (minor) = 14.21 min, tr (major) = 11.53 min.

(2R,3R,4R)-2-(4-Chlorophenyl)-3'-methyl-4-(nitromethyl)-1'-phenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11f):



Light yellow solid; m.p. 175-176 °C. $[\alpha]_D^{25} = +80$ ($c = 1.0$, CH_2Cl_2). ^1H NMR

(400 MHz, CDCl_3): δ 7.45-7.79 (m, 2H), 7.24-7.49 (m, 7H), 7.15-7.27 (m, 2H),

7.01-7.16 (m, 2H), 5.32 (s, 1H), 4.81 (dd, $J = 7.7, 3.5$ Hz, 1H), 4.67 (dd, $J = 14.2,$

7.7 Hz, 1H), 4.18 (dd, $J = 14.2, 3.6$ Hz, 1H), 2.08 (s, 3H). ^{13}C NMR (101 MHz,

CDCl_3): δ 169.68, 156.15, 152.49, 135.57, 134.24, 131.51, 129.87, 129.05, 128.62, 127.88, 127.61,


127.44, 126.83, 125.48, 125.12, 122.04, 118.98, 118.45, 116.68, 116.56, 79.49, 74.84, 58.88, 37.64,

16.73. HRMS (ESI): calcd for $\text{C}_{25}\text{H}_{20}\text{ClN}_3\text{O}_4$ $[\text{M}+\text{H}]^+$: 462.1221, found: 462.1212. HPLC (Daicel

Chiralpak ID-H: *n*-Hexane/*i*-PrOH, 93:7 v/v, flow rate = 1.0 mL/min, column pressure = 39 bar, 23°C,


UV 254 nm): tr (minor) = 22.84 min, tr (major) = 24.70 min.

(2R,3R,4R)-2-(3-Bromophenyl)-3'-methyl-4-(nitromethyl)-1'-phenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11g):




Light yellow solid; m.p. 103-104 °C. $[\alpha]_D^{25} = +40$ ($c = 1.0$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3): δ 7.40-7.67 (m, 4H), 7.29-7.40 (m, 4H), 7.14-7.29 (m, 3H), 7.12 (dd, $J = 7.9, 6.4$ Hz, 2H), 5.76 (dd, $J = 15.7, 8.9$ Hz, 1H), 5.39 (s, 1H), 4.80 (dd, $J = 7.7, 3.4$ Hz, 1H), 4.68 (dd, $J = 14.2, 7.7$ Hz, 1H), 4.19 (dd, $J = 14.2, 3.5$ Hz, 1H), 2.07 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3): δ 170.67, 157.13, 153.39, 136.56, 136.23, 132.46, 130.11, 129.94, 129.67, 129.34, 128.90, 126.52, 126.16, 125.17, 123.13, 122.46, 120.10, 119.60, 117.74, 117.63, 80.24, 75.85, 59.86, 38.53, 17.72. HRMS (ESI): calcd for $\text{C}_{25}\text{H}_{20}\text{BrN}_3\text{O}_4$ $[\text{M}+\text{H}]^+$: 506.0715, found: 506.0702. HPLC (Daicel Chiralpak ID-H: *n*-Hexane/*i*-PrOH/EtOH, 85:10:5 v/v, flow rate = 1.0 mL/min, column pressure = 44 bar, 23°C, UV 254 nm): tr (minor) = 13.44 min, tr (major) = 11.71 min.

(2R,3R,4R)-2-(4-Bromophenyl)-3'-methyl-4-(nitromethyl)-1'-phenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11h) :



Light yellow solid; m.p. 132-133 °C. $[\alpha]_D^{25} = +28$ ($c = 1.0$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3): δ 7.53 (dd, $J = 8.6, 1.0$ Hz, 2H), 7.41-7.48 (m, 2H), 7.29-7.41 (m, 5H), 7.16-7.25 (m, 2H), 7.06-7.16 (m, 2H), 5.40 (s, 1H), 4.81 (dd, $J = 7.7, 3.5$ Hz, 1H), 4.67 (dd, $J = 14.2, 7.7$ Hz, 1H), 4.18 (dd, $J = 14.2, 3.6$ Hz, 1H), 2.07 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3): δ 170.70, 157.15, 153.50, 136.59, 133.06, 131.60, 130.92, 130.09, 129.65, 128.92, 128.73, 128.12, 126.51, 126.18, 123.51, 123.08, 120.05, 119.51, 117.72, 117.60, 80.55, 75.86, 59.83, 38.68, 17.76. HRMS (ESI): calcd for $\text{C}_{25}\text{H}_{20}\text{BrN}_3\text{O}_4$ $[\text{M}+\text{H}]^+$: 506.0715, found: 506.0702. HPLC (Daicel Chiralpak ID-H: *n*-Hexane/*i*-PrOH, 90:10 v/v, flow rate = 1.0 mL/min, column pressure = 40 bar, 23°C, UV 254 nm): tr (minor) = 19.88 min, tr (major) = 21.78 min.

(2R,3R,4R)-3'-Methyl-4-(nitromethyl)-1'-phenyl-2-(m-tolyl)spiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11i):




Light yellow solid; m.p.135-136 °C. $[\alpha]_D^{25} = +80$ (c = 1.0, CH₂Cl₂). ¹H

NMR (400 MHz, CDCl₃): δ 7.28-7.53 (m, 5H), 7.15-7.28 (m, 5H), 7.02-7.15 (m, 3H), 5.40 (s, 1H), 4.82 (dd, *J* = 8.7, 3.3 Hz, 1H), 4.67 (dd, *J* = 14.1, 8.7 Hz, 1H), 4.19 (dd, *J* = 14.2, 3.3 Hz, 1H), 2.27 (s, 3H), 2.09 (s, 3H).

¹³C NMR (101 MHz, CDCl₃): δ 169.90, 156.43, 152.72, 137.05, 135.70, 132.81, 129.03, 128.49, 127.75, 127.24, 125.96, 125.44, 124.90, 122.89, 122.28, 121.79, 119.07, 118.51, 116.71, 116.57, 80.16, 74.93, 58.95, 37.49, 20.32, 16.74. HRMS (ESI): calcd for C₂₆H₂₃N₃O₄ [M+H]⁺: 442.1767, found: 442.1759. HPLC (Daicel Chiralpak ID-H: *n*-Hexane/*i*-PrOH/EtOH, 85:10:5 v/v, flow rate = 1.0 mL/min, column pressure = 44 bar, 23°C, UV 254 nm): tr (minor) = 11.79 min, tr (major) = 9.86 min.

(2R,3R,4R)-3'-Methyl-4-(nitromethyl)-1'-phenyl-2-(p-tolyl)spiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11j) :




Light yellow solid; m.p. 154-155 °C. $[\alpha]_D^{25} = +60$ (c = 1.0, CH₂Cl₂). ¹H

NMR (400 MHz, CDCl₃): δ 7.25-7.61 (m, 7H), 7.15-7.22 (m, 2H), 7.02-7.14 (m, 4H), 5.41 (s, 1H), 4.81 (dd, *J* = 7.8, 3.4 Hz, 1H), 4.67 (dd, *J* = 14.2, 7.9 Hz, 1H), 4.18 (dd, *J* = 14.2, 3.4 Hz, 1H), 2.29 (s, 3H), 2.10 (s, 3H). ¹³C


NMR (101 MHz, CDCl₃): δ 169.90, 156.43, 152.72, 137.05, 135.70, 132.81, 129.03, 128.49, 127.75, 127.24, 125.96, 125.44, 124.90, 122.89, 122.28, 121.79, 119.07, 118.51, 116.71, 116.57, 80.16, 74.93, 58.95, 37.49, 20.32, 16.74. HRMS (ESI): calcd for C₂₆H₂₃N₃O₄ [M+H]⁺: 442.1767, found: 442.1759. HPLC (Daicel Chiralpak ID-H: *n*-Hexane/*i*-PrOH/EtOH, 85:10:5 v/v, flow rate = 1.0 mL/min, column pressure = 44 bar, 23 °C, UV 254 nm): tr (minor) =14.65 min, tr (major) = 12.09 min.

(2R,3R,4R)-3'-Methyl-4-(nitromethyl)-2-(3-nitrophenyl)-1'-phenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11k):




Light yellow solid; m.p. 168-169 °C. $[\alpha]_D^{25} = +60$ ($c = 1.0$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3): δ 8.36 (d, $J = 11.7$ Hz, 1H), 8.16 (d, $J = 8.1$ Hz, 1H), 7.44-7.95 (m, 4H), 7.24-7.44 (m, 4H), 7.10-7.21 (m, 3H), 5.54 (s, 1H), 4.85 (dd, $J = 7.2, 3.2$ Hz, 1H), 4.70 (dd, $J = 14.2, 7.2$ Hz, 1H), 4.20 (dd, $J = 14.2, 3.2$ Hz, 1H), 2.11 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3): δ 170.46, 157.00, 153.09, 148.12, 136.22, 132.85, 130.28, 129.86, 129.49, 129.42, 128.98, 126.57, 126.25, 124.30, 123.44, 121.31, 119.63, 119.16, 117.80, 117.71, 79.86, 75.78, 59.88, 38.51, 17.76. HRMS (ESI): calcd for $\text{C}_{25}\text{H}_{20}\text{N}_3\text{O}_5$ $[\text{M}+\text{H}]^+$: 473.1461, found: 473.1454. HPLC (Daicel Chiralpak ID-H: *n*-Hexane/*i*-PrOH/EtOH, 85:10:5 v/v, flow rate = 1.0 mL/min, column pressure = 45 bar, 23 °C, UV 254 nm): tr (minor) = 36.77 min, tr (major) = 31.81 min.

(2R,3R,4R)-2-(Furan-3-yl)-3'-methyl-4-(nitromethyl)-1'-phenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11l):



Yellow solid; m.p. 125-126 °C. $[\alpha]_D^{25} = +17$ ($c = 1.0$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3): δ 7.70 (dd, $J = 5.6, 3.4$ Hz, 1H), 7.59 (dd, $J = 5.6, 3.4$ Hz, 1H), 7.37 (qd, $J = 11.6, 7.2$ Hz, 4H), 7.05-7.25 (m, 4H), 6.48 (dd, $J = 7.6, 3.3$ Hz, 1H), 6.27-6.36 (m, 1H), 5.45 (s, 1H), 4.72 (dd, $J = 8.7, 2.9$ Hz, 1H), 4.63 (dd, $J = 14.0, 8.7$ Hz, 1H), 4.18 (dd, $J = 14.0, 3.0$ Hz, 1H), 2.11 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3): δ 169.43, 159.24, 152.27, 146.17, 142.70, 135.92, 129.05, 128.59, 127.82, 125.35, 124.95, 121.91, 118.85, 117.98, 116.62, 115.85, 109.56, 109.27, 74.56, 69.62, 56.78, 37.79, 16.21. HRMS (ESI): calcd for $\text{C}_{23}\text{H}_{19}\text{N}_3\text{O}_5$ $[\text{M}+\text{Na}]^+$: 440.1217, found: 440.1214. HPLC (Daicel Chiralpak AD-H: *n*-Hexane/*i*-PrOH, 95:5 v/v, flow rate = 1.0 mL/min, column pressure = 37 bar, 23°C, UV 254 nm): tr (minor) = 44.67 min, tr (major) = 27.80 min.


(3R,4R)-2,2,3'-Trimethyl-4-(nitromethyl)-1'-phenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11m):



Yellow solid; m.p. 97-98 °C. $[\alpha]_D^{25} = -144$ ($c = 1.0$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3): δ 7.93 (d, $J = 8.1$ Hz, 2H), 7.46 (t, $J = 7.9$ Hz, 2H),


7.22-7.34 (m, 4H), 7.11 (d, $J = 7.7$ Hz, 1H), 7.04 (t, $J = 7.2$ Hz, 1H), 6.94 (d, $J = 8.0$ Hz, 1H), 4.60 (dd, $J = 14.1, 7.7$ Hz, 1H), 4.49 (dd, $J = 7.3, 2.2$ Hz, 1H), 4.05 (dd, $J = 14.1, 2.9$ Hz, 1H), 2.00 (s, 3H), 1.61 (s, 3H), 1.58 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3): δ 169.88, 158.76, 151.31, 136.28, 128.58, 128.01, 125.39, 124.83, 121.23, 118.28, 118.09, 117.11, 76.19, 75.84, 75.39, 35.22, 23.24, 21.68, 16.31. HRMS (ESI): calcd for $\text{C}_{21}\text{H}_{21}\text{N}_3\text{O}_4$ $[\text{M}+\text{Na}]^+$: 402.1424, found: 402.1422. HPLC (Daicel Chiralpak ID-H: *n*-Hexane/*i*-PrOH/EtOH, 85:10:5 v/v, flow rate = 1.0 mL/min, column pressure = 40 bar, 23 °C, UV 254 nm): tr (major) = 5.42 min.

(2R,3R,4R)-4-(Nitromethyl)-1',2,3'-triphenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11n):



Light yellow solid; m.p. 139-140 °C. $[\alpha]_{\text{D}}^{25} = -32$ ($c = 1.0$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3): δ 7.73 (dd, $J = 5.3, 3.6$ Hz, 2H), 7.65 (d, $J = 7.7$ Hz, 1H), 7.57 (dd, $J = 12.3, 7.8$ Hz, 4H), 7.31-7.46 (m, 7H), 7.21 (t, $J = 9.9$ Hz, 4H), 7.06 (dd, $J = 30.0, 8.2$ Hz, 1H), 5.36 (s, 1H), 4.95 (dd, $J = 5.8, 6.4$ Hz, 1H), 4.76 (dd, $J = 19.6, 5.8$ Hz, 1H), 4.08 (dd, $J = 19.6, 6.4$ Hz, 1H). ^{13}C NMR (101 MHz, CDCl_3): δ 170.67, 166.75, 132.64, 131.44, 129.86, 129.54, 129.15, 128.62, 128.42, 128.33, 128.25, 127.79, 127.70, 127.28, 127.13, 126.99, 126.65, 126.60, 125.95, 125.27, 122.27, 121.98, 119.58, 119.27, 117.35, 117.09, 81.74, 78.49, 67.15, 37.72. HRMS (ESI): calcd for $\text{C}_{30}\text{H}_{23}\text{N}_3\text{O}_5$ $[\text{M}+\text{Na}]^+$: 512.1586, found: 512.1585. HPLC (Daicel Chiralpak AD-H: *n*-Hexane/*i*-PrOH, 95:5 v/v, flow rate = 1.0 mL/min, column pressure = 37bar, 23 °C, UV 254 nm): tr (minor) = 32.44 min, tr (major) = 26.48 min.


(2R,3R,4R)-6-Bromo-3'-methyl-4-(nitromethyl)-1',2-diphenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11o):



Light yellow solid; m.p. 170-171 °C. $[\alpha]_{\text{D}}^{25} = +48$ ($c = 1.0$, CH_2Cl_2). ^1H NMR (400 MHz, CDCl_3): δ 7.34-7.53 (m, 5H), 7.26-7.34 (m, 6H), 7.13-7.22 (m, 1H), 7.00 (d, $J = 8.7$ Hz, 1H), 5.40 (s, 1H), 4.78 (dd, $J = 7.5, 3.5$ Hz, 1H), 4.66 (dd, $J = 14.5, 7.6$ Hz, 1H), 4.19 (dd, $J = 14.4, 3.6$ Hz, 1H), 2.11 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3): δ 170.50, 156.85, 152.95, 136.57, 133.43, 133.13, 132.70, 131.84, 129.55, 129.39, 128.83, 128.45, 127.04, 126.39, 126.12, 121.58, 120.18, 119.62,

119.41, 115.08, 81.50, 75.62, 59.68, 38.44, 17.81. HRMS (ESI): calcd for $C_{25}H_{20}BrN_3O_4$ $[M+H]^+$: 506.0715, found: 506.0702. HPLC (Daicel Chiralpak AD-H: *n*-Hexane/*i*-PrOH, 95:5 v/v, flow rate = 1.0 mL/min, column pressure = 37 bar, 23 °C, UV 254 nm): *tr* (minor) = 31.89 min, *tr* (major) = 25.96 min.

(2R,3R,4R)-3'-Methyl-6-nitro-4-(nitromethyl)-1',2-diphenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11p):



Yellow solid; m.p. 209-210 °C. $[\alpha]_D^{25} = +53$ (*c* = 1.0, CH_2Cl_2). 1H

NMR (400 MHz, DMSO): δ 8.70 (s, 1H), 8.22 (d, *J* = 9.4 Hz, 1H),

7.70 (d, *J* = 13.3 Hz, 1H), 7.24-7.36 (m, 9H), 7.15 (t, *J* = 7.6 Hz, 1H),

5.85 (dd, *J* = 15.2, 9.2 Hz, 1H), 5.81 (s, 1H), 5.13 (dd, *J* = 17.4, 15.2 Hz,

1H), 4.41 (dd, *J* = 17.4, 9.2 Hz, 1H), 1.99 (s, 3H). ^{13}C NMR (101 MHz, DMSO): δ 170.84, 159.64,

142.33, 136.92, 133.99, 132.18, 132.00, 129.77, 129.31, 129.14, 128.66, 128.19, 127.82, 126.16,


125.35, 119.64, 119.48, 118.49, 77.47, 75.27, 56.58, 36.00, 17.13. HRMS (ESI): calcd for $C_{25}H_{20}N_4O_6$

$[M+Na]^+$: 495.1281, found: 496.1275. HPLC (Daicel Chiralpak AD-H: *n*-Hexane/*i*-PrOH, 95:5 v/v,

flow rate = 1.0 mL/min, column pressure = 37bar, 23 °C, UV 254 nm): *tr* (minor) = 69.38 min, *tr*

(major) = 49.21 min.

(2R,3R,4R)-3'-Methyl-4-(nitromethyl)-1',2-diphenyl-2,4-dihydrospiro[benzo[*g*]chromene-3,4'-pyrazol]-5'(1'H)-one (11q):



Yellow solid; m.p. 176-177 °C. $[\alpha]_D^{25} = +68$ (*c* = 1.0, CH_2Cl_2). 1H NMR (400

MHz, $CDCl_3$): δ 7.91 (d, *J* = 8.0 Hz, 1H), 7.86 (d, *J* = 9.0 Hz, 1H), 7.73 (d, *J*

= 8.4 Hz, 1H), 7.62 (t, *J* = 7.5 Hz, 1H), 7.47-7.52 (m, 1H), 7.44 (d, *J* = 4.1 Hz,

2H), 7.37 (d, *J* = 7.9 Hz, 2H), 7.22-7.34 (m, 6H), 7.14 (t, *J* = 7.4 Hz, 1H),

5.77 (dd, *J* = 17.0, 9.8 Hz, 1H), 5.44 (s, 1H), 4.74 (t, *J* = 12.2 Hz, 2H), 1.93 (s, 3H). ^{13}C NMR (101


MHz, $CDCl_3$): δ 171.08, 158.91, 152.38, 136.68, 133.79, 130.99, 130.80, 130.23, 129.72, 129.41,

128.71, 128.46, 128.41, 127.08, 125.93, 124.79, 120.57, 120.16, 118.39, 108.23, 77.23, 73.74, 55.57,

33.64, 17.07. HRMS (ESI): calcd for $C_{29}H_{23}N_3O_6$ $[M+Na]^+$: 500.1586, found: 500.1583. HPLC (Daicel

Chiralpak AD-H: *n*-Hexane/*i*-PrOH, 95:5 v/v, flow rate = 1.0 mL/min, column pressure = 37 bar, 23 °C, UV 254 nm): tr (minor) = 36.82 min, tr (major) = 29.99 min.

(2R,3R,4R)-6,8-Di-*tert*-butyl-3'-methyl-4-(nitromethyl)-1',2-diphenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11r):




Yellow solid; m.p. 136-137 °C. $[\alpha]_D^{25} = +20$ (c = 1.0, CH₂Cl₂). ¹H

NMR (400 MHz, CDCl₃): δ 7.59 (d, *J* = 8.0 Hz, 1H), 7.41-7.44 (m, 1H), 7.37-7.40 (m, 1H), 7.32-7.36 (m, 3H), 7.26-7.32 (m, 4H), 7.12-7.21 (m, 1H), 7.07 (s, 1H), 5.03 (s, 1H), 4.82 (dd, *J* = 14.0, 9.0 Hz, 1H),

4.45 (dd, *J* = 9.0, 3.7 Hz, 1H), 4.34 (dd, *J* = 14.0, 3.7 Hz, 1H), 2.04 (s, 3H), 1.42 (s, 3H), 1.38 (s, 6H), 1.35 (s, 3H), 1.34 (s, 6H). ¹³C NMR (101 MHz, CDCl₃): δ 170.03, 158.16, 149.68, 143.85, 137.05, 135.66, 133.04, 128.18, 127.61, 127.23, 126.24, 124.83, 123.26, 122.57, 119.20, 115.67, 76.62, 75.52, 55.72, 36.28, 34.14, 33.52, 30.46, 28.79, 15.88. HRMS (ESI): calcd for C₃₃H₃₇N₃O₆ [M+Na]⁺: 562.282, found: 562.2680. HPLC (Daicel Chiralpak ID-H: *n*-Hexane/*i*-PrOH/EtOH, 85:10:5 v/v, flow rate = 1.0 mL/min, column pressure = 44 bar, 23 °C, UV 254 nm): tr (minor) = 3.77 min, tr (major) = 5.01 min.

(2R,3R,4R)-2-(4-Chlorophenyl)-7-methoxy-3'-methyl-4-(nitromethyl)-1'-phenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11s):




Light yellow solid; m.p. 135-136 °C. $[\alpha]_D^{25} = +9$ (c = 1.0, CH₂Cl₂). ¹H

NMR (400 MHz, CDCl₃): δ 7.46-7.58 (m, 2H), 7.23-7.40 (m, 7H), 7.07 (d, *J* = 8.2 Hz, 1H), 6.55-6.76 (m, 2H), 5.40 (s, 1H), 4.72 (dd, *J* = 7.8, 4.2 Hz, 1H), 4.64 (dd, *J* = 14.4, 4.2 Hz, 1H), 4.16 (d, *J* = 14.4, 7.8 Hz, 1H), 3.84 (s, 3H), 2.09 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ

170.74, 160.54, 157.17, 154.51, 136.61, 135.28, 132.53, 130.92, 130.03, 128.91, 128.79, 128.64, 128.47, 127.87, 127.24, 126.13, 119.48, 111.14, 110.01, 102.20, 80.70, 76.00, 59.95, 55.49, 38.44, 17.80. HRMS (ESI): calcd for C₂₆H₂₂ClN₃O₅ [M+ H]⁺: 492.1326, found: 492.1315. HPLC (Daicel Chiralpak ID-H: *n*-Hexane/*i*-PrOH/EtOH, 85:10:5 v/v, flow rate = 1.0 mL/min, column pressure = 44 bar, 23 °C, UV 254 nm): tr (minor) = 13.71 min, tr (major) = 9.94 min.

(2R,3R,4R)-7-Methoxy-3'-methyl-4-(nitromethyl)-1'-phenyl-2-(p-tolyl)spiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11t):



Light yellow solid; m.p. 145-146 °C. $[\alpha]_D^{25} = +40$ ($c = 1.0$, CH_2Cl_2). ^1H

NMR (400 MHz, CDCl_3): δ 7.51 (dd, $J = 5.6, 3.3$ Hz, 2H), 7.23-7.43

(m, 6H), 7.18 (t, $J = 7.4$ Hz, 1H), 7.01-7.15 (m, 3H), 5.39 (s, 1H), 4.73

(dd, $J = 7.6, 3.4$ Hz, 1H), 4.62 (dd, $J = 14.0, 7.6$ Hz, 1H), 4.15 (dd, $J =$

14.0, 3.4 Hz, 1H), 3.84 (s, 3H), 2.28 (s, 3H), 2.20 (s, 3H), 2.10 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3): δ

170.96, 160.46, 157.51, 154.85, 139.24, 136.78, 130.93, 129.99, 129.07, 128.77, 127.19, 126.95,

126.35, 125.91, 120.09, 119.61, 111.31, 110.32, 109.77, 102.18, 81.40, 76.10, 60.07, 55.46, 38.48,


21.16, 17.83. HRMS (ESI): calcd for $\text{C}_{27}\text{H}_{25}\text{N}_3\text{O}_5$ $[\text{M}+\text{H}]^+$: 472.1872, found: 472.1865. HPLC (Daicel

Chiralpak ID-H: *n*-Hexane/*i*-PrOH/EtOH, 85:10:5 v/v, flow rate = 1.0 mL/min, column pressure = 44


bar, 23 °C, UV 254 nm): t_r (minor) = 13.93 min, t_r (major) = 9.41 min.

¹H-NMR and ¹³C-NMR Spectra


(2R,3R,4R)-3'-Methyl-4-(nitromethyl)-1',2-diphenyl spiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11a):




(2R,3R,4R)-2-(2-Fluorophenyl)-3'-methyl-4-(nitromethyl)-1'-phenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11b):




(2R,3R,4R)-2-(4-Fluorophenyl)-3'-methyl-4-(nitromethyl)-1'-phenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11c):




(2R,3R,4R)-2-(2-Chlorophenyl)-3'-methyl-4-(nitromethyl)-1'-phenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11d):




(2R,3R,4R)-2-(3-Chlorophenyl)-3'-methyl-4-(nitromethyl)-1'-phenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11e):




(2R,3R,4R)-2-(4-Chlorophenyl)-3'-methyl-4-(nitromethyl)-1'-phenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11f):




(2R,3R,4R)-2-(3-Bromophenyl)-3'-methyl-4-(nitromethyl)-1'-phenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11g):




(2R,3R,4R)-2-(4-Bromophenyl)-3'-methyl-4-(nitromethyl)-1'-phenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11h):





(2R,3R,4R)-3'-Methyl-4-(nitromethyl)-1'-phenyl-2-(m-tolyl)spiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11i):





(2R,3R,4R)-3'-Methyl-4-(nitromethyl)-1'-phenyl-2-(p-tolyl)spiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11j):



(2R,3R,4R)-3'-Methyl-4-(nitromethyl)-2-(3-nitrophenyl)-1'-phenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11k):




(2R,3R,4R)-2-(Furan-3-yl)-3'-methyl-4-(nitromethyl)-1'-phenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11l):





(3R,4R)-2,2,3'-Trimethyl-4-(nitromethyl)-1'-phenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one



(11m):





(2R,3R,4R)-4-(Nitromethyl)-1',2,3'-triphenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11n):




(2R,3R,4R)-6-Bromo-3'-methyl-4-(nitromethyl)-1',2-diphenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11o):




(2R,3R,4R)-3'-Methyl-6-nitro-4-(nitromethyl)-1',2-diphenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11p):




(2R,3R,4R)-3'-Methyl-4-(nitromethyl)-1',2-diphenyl-2,4-dihydrospiro[benzo[g]chromene-3,4'-pyrazol]-5'(1'H)-one (11q):




(2R,3R,4R)-6,8-Di-*tert*-butyl-3'-methyl-4-(nitromethyl)-1',2-diphenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11r):



(2R,3R,4R)-2-(4-Chlorophenyl)-7-methoxy-3'-methyl-4-(nitromethyl)-1'-phenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11s):




(2R,3R,4R)-7-Methoxy-3'-methyl-4-(nitromethyl)-1'-phenyl-2-(p-tolyl)spiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11t):




HPLC Spectra

(2R,3R,4R)-3'-Methyl-4-(nitromethyl)-1',2-diphenyl spiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11a):

RACEMIC 11a




CHIRAL 11a




(2R,3R,4R)-2-(2-Fluorophenyl)-3'-methyl-4-(nitromethyl)-1'-phenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11b):

RACEMIC 11b




CHIRAL 11b




(2R,3R,4R)-2-(4-Fluorophenyl)-3'-methyl-4-(nitromethyl)-1'-phenylspiro[chroman-3,4'-pyrazol]-5'-(1'H)-one (11c):

RACEMIC 11c




CHIRAL 11c




(2R,3R,4R)-2-(2-Chlorophenyl)-3'-methyl-4-(nitromethyl)-1'-phenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11d):

RACEMIC 11d




CHIRAL 11d




(2R,3R,4R)-2-(3-Chlorophenyl)-3'-methyl-4-(nitromethyl)-1'-phenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11e):

RACEMIC 11e




CHIRAL 11e




(2R,3R,4R)-2-(4-Chlorophenyl)-3'-methyl-4-(nitromethyl)-1'-phenylspiro[chroman-3,4'-pyrazol]-5'-(1'H)-one (11f):

RACEMIC 11f



Peak	Reten.Time [min]	Peak.Width [min]	Area [mAU]	Height [mAU]	Area [%]
1	22.775	0.5741	30.29632	6.77539e-1	49.7493
2	25.822	2.0347	30.60162	2.50662e-1	50.2507


CHIRAL11f




Peak	Reten.Time [min]	Peak.Width [min]	Area [mAU]	Height [mAU]	Area [%]
1	22.835	0.6405	45.12573	1.02752	0.9583
2	24.697	1.8536	4664.00537	35.89781	99.0417

(2R,3R,4R)-2-(3-Bromophenyl)-3'-methyl-4-(nitromethyl)-1'-phenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11g):

RACEMIC 11g




CHIRAL 11g




(2R,3R,4R)-2-(4-Bromophenyl)-3'-methyl-4-(nitromethyl)-1'-phenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11h):

RACEMIC 11h




CHIRAL 11h




(2R,3R,4R)-3'-Methyl-4-(nitromethyl)-1'-phenyl-2-(m-tolyl)spiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11i):

RACEMIC 11i




CHIRAL 11i




(2R,3R,4R)-3'-Methyl-4-(nitromethyl)-1'-phenyl-2-(p-tolyl)spiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11j):

RACEMIC 11j



CHIRAL 11j




RACEMIC 11k




(2R,3R,4R)-2-(Furan-3-yl)-3'-methyl-4-(nitromethyl)-1'-phenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11l):

RACEMIC 11l




CHIRAL 11l




(3R,4R)-2,2,3'-Trimethyl-4-(nitromethyl)-1'-phenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one
(11m):

RACEMIC 11m




CHIRAL 11m




(2R,3R,4R)-4-(Nitromethyl)-1',2,3'-triphenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11n):

RACEMIC 11n




CHIRAL 11n




(2R,3R,4R)-6-Bromo-3'-methyl-4-(nitromethyl)-1',2-diphenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11o):

RACEMIC 11o




CHIRAL 11o




(2R,3R,4R)-3'-Methyl-6-nitro-4-(nitromethyl)-1',2-diphenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11p):

RACEMIC 11p



Peak	Reten.Time [min]	Peak.Width [min]	Area [mAU]	Height [mAU]	Area [%]
1	49.698	1.4301	397.34888	3.96882	50.1327
2	70.149	1.7688	395.24466	2.80058	49.8673


CHIRAL 11p




Peak	Reten.Time [min]	Peak.Width [min]	Area [mAU]	Height [mAU]	Area [%]
1	49.208	1.5144	907.44434	8.86594	84.8333
2	69.381	1.5945	162.23466	1.20018	15.1667

(2R,3R,4R)-3'-Methyl-4-(nitromethyl)-1',2-diphenyl-2,4-dihydrospiro[benzo[g]chromene-3,4'-pyrazol]-5'(1'H)-one (11q):

RACEMIC 11q




CHIRAL 11q




(2R,3R,4R)-6,8-Di-*tert*-butyl-3'-methyl-4-(nitromethyl)-1',2-diphenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11r):

RACEMIC 11r




CHIRAL 11r




(2R,3R,4R)-2-(4-Chlorophenyl)-7-methoxy-3'-methyl-4-(nitromethyl)-1'-phenylspiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11s):

RACEMIC 11s




CHIRAL 11s




(2R,3R,4R)-7-Methoxy-3'-methyl-4-(nitromethyl)-1'-phenyl-2-(p-tolyl)spiro[chroman-3,4'-pyrazol]-5'(1'H)-one (11t):

RACEMIC 11t



CHIRAL 11t



X-ray crystal structure of **11a**;

Crystallographic data for the structural analysis of compound **11a** has been deposited at the Cambridge Crystallographic Data Centre as No. CCDC 1428773. These data can be obtained free of charge by contacting The Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033; E-mail: deposit@ccdc.cam.ac.uk.




Table 1. Crystal data and structure refinement for shelxl.

Identification code	shelxl
Empirical formula	C ₂₅ H ₂₁ N ₃ O ₄
Formula weight	427.45
Temperature	173(2) K
Wavelength	1.54187 Å
Crystal system, space group	Monoclinic, P2(1)
Unit cell dimensions	a = 9.007(4) Å alpha = 90 deg. b = 13.691(4) Å beta = 112.6366(10) deg. c = 11.577(4) Å gamma = 90 deg.
Volume	1317.6(8) Å ³
Z, Calculated density	2, 1.264 Mg/m ³
Absorption coefficient	0.708 mm ⁻¹

F(000)	532
Crystal size	0.260 x 0.200 x 0.160 mm
Theta range for data collection	6.228 to 77.702 deg.
Limiting indices	-11 ≤ h ≤ 11, -17 ≤ k ≤ 14, -14 ≤ l ≤ 14
Reflections collected / unique	22397 / 4797 [R(int) = 0.0235]
Completeness to theta = 67.687	99.6 %
Absorption correction	Semi-empirical from equivalents
Max. and min. transmission	0.893 and 0.778
Refinement method	Full-matrix least-squares on F ²
Data / restraints / parameters	4797 / 1 / 338
Goodness-of-fit on F ²	1.051
Final R indices [I > 2σ(I)]	R1 = 0.0309, wR2 = 0.0837
R indices (all data)	R1 = 0.0312, wR2 = 0.0840
Absolute structure parameter	0.00(4)
Extinction coefficient	0.0184(11)
Largest diff. peak and hole	0.208 and -0.175 e.Å ⁻³